EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer

Chun Chia Cheng, Kuei Fang Chou, Cheng Wen Wu, Nai Wen Su, Cheng Liang Peng, Ying Wen Su, Jungshan Chang, Ai Sheng Ho, Huan Chau Lin, Caleb Gon Shen Chen, Bi Ling Yang, Yu Cheng Chang, Ya Wen Chiang, Ken Hong Lim, Yi Fang Chang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives YM155, an inhibitor of interleukin enhancer-binding factor 3 (ILF3), significantly suppresses cancer stemness property, implying that ILF3 contributes to cell survival of cancer stem cells. However, the molecular function of ILF3 inhibiting cancer stemness remains unclear. This study aimed to uncover the potential function of ILF3 involving in cell survival of epidermal growth factor receptor (EGFR)-positive lung stem-like cancer, and to investigate the potential role to improve the efficacy of anti-EGFR therapeutics. Materials and methods The association of EGFR and ILF3 in expression and regulations was first investigated in this study. Lung cancer A549 cells with deprivation of ILF3 were created by the gene-knockdown method and then RNAseq was applied to identify the putative genes regulated by ILF3. Meanwhile, HCC827- and A549-derived cancer stem-like cells were used to investigate the role of ILF3 in the formation of cancer stem-like tumorspheres. Results We found that EGFR induced ILF3 expression, and YM155 reduced EGFR expression. The knockdown of ILF3 reduced not only EGFR expression in mRNA and protein levels, but also cell proliferation in vitro and in vivo, demonstrating that ILF3 may play an important role in contributing to cancer cell survival. Moreover, the knockdown and inhibition of ILF3 by shRNA and YM155, respectively, reduced the formation and survival of HCC827- and A549-derived tumorspheres through inhibiting ErbB3 (HER3) expression, and synergized the therapeutic efficacy of afatinib, a tyrosine kinase inhibitor, against EGFR-positive A549 lung cells. Conclusion This study demonstrated that ILF3 plays an oncogenic like role in maintaining the EGFR-mediated cellular pathway, and can be a therapeutic target to improve the therapeutic efficacy of afatinib. Our results suggested that YM155, an ILF3 inhibitor, has the potential for utilization in cancer therapy against EGFR-positive lung cancers.

Original languageEnglish
Pages (from-to)80-89
Number of pages10
JournalLung Cancer
Volume116
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Nuclear Factor 90 Proteins
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Neoplasms
Therapeutics
Cell Survival
Neoplastic Stem Cells
Lung Neoplasms
Gene Knockdown Techniques

Keywords

  • Afatinib
  • EGFR
  • ILF3
  • Lung cancer
  • YM155

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer. / Cheng, Chun Chia; Chou, Kuei Fang; Wu, Cheng Wen; Su, Nai Wen; Peng, Cheng Liang; Su, Ying Wen; Chang, Jungshan; Ho, Ai Sheng; Lin, Huan Chau; Chen, Caleb Gon Shen; Yang, Bi Ling; Chang, Yu Cheng; Chiang, Ya Wen; Lim, Ken Hong; Chang, Yi Fang.

In: Lung Cancer, Vol. 116, 01.02.2018, p. 80-89.

Research output: Contribution to journalArticle

Cheng, Chun Chia ; Chou, Kuei Fang ; Wu, Cheng Wen ; Su, Nai Wen ; Peng, Cheng Liang ; Su, Ying Wen ; Chang, Jungshan ; Ho, Ai Sheng ; Lin, Huan Chau ; Chen, Caleb Gon Shen ; Yang, Bi Ling ; Chang, Yu Cheng ; Chiang, Ya Wen ; Lim, Ken Hong ; Chang, Yi Fang. / EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer. In: Lung Cancer. 2018 ; Vol. 116. pp. 80-89.
@article{dc2a7e9b217248faa0eb221d17977f8f,
title = "EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer",
abstract = "Objectives YM155, an inhibitor of interleukin enhancer-binding factor 3 (ILF3), significantly suppresses cancer stemness property, implying that ILF3 contributes to cell survival of cancer stem cells. However, the molecular function of ILF3 inhibiting cancer stemness remains unclear. This study aimed to uncover the potential function of ILF3 involving in cell survival of epidermal growth factor receptor (EGFR)-positive lung stem-like cancer, and to investigate the potential role to improve the efficacy of anti-EGFR therapeutics. Materials and methods The association of EGFR and ILF3 in expression and regulations was first investigated in this study. Lung cancer A549 cells with deprivation of ILF3 were created by the gene-knockdown method and then RNAseq was applied to identify the putative genes regulated by ILF3. Meanwhile, HCC827- and A549-derived cancer stem-like cells were used to investigate the role of ILF3 in the formation of cancer stem-like tumorspheres. Results We found that EGFR induced ILF3 expression, and YM155 reduced EGFR expression. The knockdown of ILF3 reduced not only EGFR expression in mRNA and protein levels, but also cell proliferation in vitro and in vivo, demonstrating that ILF3 may play an important role in contributing to cancer cell survival. Moreover, the knockdown and inhibition of ILF3 by shRNA and YM155, respectively, reduced the formation and survival of HCC827- and A549-derived tumorspheres through inhibiting ErbB3 (HER3) expression, and synergized the therapeutic efficacy of afatinib, a tyrosine kinase inhibitor, against EGFR-positive A549 lung cells. Conclusion This study demonstrated that ILF3 plays an oncogenic like role in maintaining the EGFR-mediated cellular pathway, and can be a therapeutic target to improve the therapeutic efficacy of afatinib. Our results suggested that YM155, an ILF3 inhibitor, has the potential for utilization in cancer therapy against EGFR-positive lung cancers.",
keywords = "Afatinib, EGFR, ILF3, Lung cancer, YM155",
author = "Cheng, {Chun Chia} and Chou, {Kuei Fang} and Wu, {Cheng Wen} and Su, {Nai Wen} and Peng, {Cheng Liang} and Su, {Ying Wen} and Jungshan Chang and Ho, {Ai Sheng} and Lin, {Huan Chau} and Chen, {Caleb Gon Shen} and Yang, {Bi Ling} and Chang, {Yu Cheng} and Chiang, {Ya Wen} and Lim, {Ken Hong} and Chang, {Yi Fang}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.lungcan.2017.12.017",
language = "English",
volume = "116",
pages = "80--89",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer

AU - Cheng, Chun Chia

AU - Chou, Kuei Fang

AU - Wu, Cheng Wen

AU - Su, Nai Wen

AU - Peng, Cheng Liang

AU - Su, Ying Wen

AU - Chang, Jungshan

AU - Ho, Ai Sheng

AU - Lin, Huan Chau

AU - Chen, Caleb Gon Shen

AU - Yang, Bi Ling

AU - Chang, Yu Cheng

AU - Chiang, Ya Wen

AU - Lim, Ken Hong

AU - Chang, Yi Fang

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Objectives YM155, an inhibitor of interleukin enhancer-binding factor 3 (ILF3), significantly suppresses cancer stemness property, implying that ILF3 contributes to cell survival of cancer stem cells. However, the molecular function of ILF3 inhibiting cancer stemness remains unclear. This study aimed to uncover the potential function of ILF3 involving in cell survival of epidermal growth factor receptor (EGFR)-positive lung stem-like cancer, and to investigate the potential role to improve the efficacy of anti-EGFR therapeutics. Materials and methods The association of EGFR and ILF3 in expression and regulations was first investigated in this study. Lung cancer A549 cells with deprivation of ILF3 were created by the gene-knockdown method and then RNAseq was applied to identify the putative genes regulated by ILF3. Meanwhile, HCC827- and A549-derived cancer stem-like cells were used to investigate the role of ILF3 in the formation of cancer stem-like tumorspheres. Results We found that EGFR induced ILF3 expression, and YM155 reduced EGFR expression. The knockdown of ILF3 reduced not only EGFR expression in mRNA and protein levels, but also cell proliferation in vitro and in vivo, demonstrating that ILF3 may play an important role in contributing to cancer cell survival. Moreover, the knockdown and inhibition of ILF3 by shRNA and YM155, respectively, reduced the formation and survival of HCC827- and A549-derived tumorspheres through inhibiting ErbB3 (HER3) expression, and synergized the therapeutic efficacy of afatinib, a tyrosine kinase inhibitor, against EGFR-positive A549 lung cells. Conclusion This study demonstrated that ILF3 plays an oncogenic like role in maintaining the EGFR-mediated cellular pathway, and can be a therapeutic target to improve the therapeutic efficacy of afatinib. Our results suggested that YM155, an ILF3 inhibitor, has the potential for utilization in cancer therapy against EGFR-positive lung cancers.

AB - Objectives YM155, an inhibitor of interleukin enhancer-binding factor 3 (ILF3), significantly suppresses cancer stemness property, implying that ILF3 contributes to cell survival of cancer stem cells. However, the molecular function of ILF3 inhibiting cancer stemness remains unclear. This study aimed to uncover the potential function of ILF3 involving in cell survival of epidermal growth factor receptor (EGFR)-positive lung stem-like cancer, and to investigate the potential role to improve the efficacy of anti-EGFR therapeutics. Materials and methods The association of EGFR and ILF3 in expression and regulations was first investigated in this study. Lung cancer A549 cells with deprivation of ILF3 were created by the gene-knockdown method and then RNAseq was applied to identify the putative genes regulated by ILF3. Meanwhile, HCC827- and A549-derived cancer stem-like cells were used to investigate the role of ILF3 in the formation of cancer stem-like tumorspheres. Results We found that EGFR induced ILF3 expression, and YM155 reduced EGFR expression. The knockdown of ILF3 reduced not only EGFR expression in mRNA and protein levels, but also cell proliferation in vitro and in vivo, demonstrating that ILF3 may play an important role in contributing to cancer cell survival. Moreover, the knockdown and inhibition of ILF3 by shRNA and YM155, respectively, reduced the formation and survival of HCC827- and A549-derived tumorspheres through inhibiting ErbB3 (HER3) expression, and synergized the therapeutic efficacy of afatinib, a tyrosine kinase inhibitor, against EGFR-positive A549 lung cells. Conclusion This study demonstrated that ILF3 plays an oncogenic like role in maintaining the EGFR-mediated cellular pathway, and can be a therapeutic target to improve the therapeutic efficacy of afatinib. Our results suggested that YM155, an ILF3 inhibitor, has the potential for utilization in cancer therapy against EGFR-positive lung cancers.

KW - Afatinib

KW - EGFR

KW - ILF3

KW - Lung cancer

KW - YM155

UR - http://www.scopus.com/inward/record.url?scp=85040001244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040001244&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2017.12.017

DO - 10.1016/j.lungcan.2017.12.017

M3 - Article

AN - SCOPUS:85040001244

VL - 116

SP - 80

EP - 89

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -